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http://www.biomedcentral.com/1756-0500/7/30RESEARCH ARTICLE Open AccessCaffeine administration does not alter salivary
α-amylase activity in young male daily caffeine
consumers
Laura Cousino Klein1,2*, Courtney A Whetzel1, Jeanette M Bennett1, Frank E Ritter3, Urs M Nater4
and Michael Schoelles5Abstract
Background: To follow up on a recent report from our lab [Hum Psychopharmacol 25:359–367, 2010.] we
examined the effects of caffeine on salivary α-amylase (sAA) activity in response to an engaging, non-stressful task
in healthy young males (age 18–30 yrs) who consumed caffeine on a daily basis. Using a placebo-controlled,
double-blind, between-subjects design, 45 men received either placebo, 200 mg or 400 mg of caffeine (Vivarin®).
Participants then rested for 20 minutes, and performed a 20-minute computerized air traffic controller-like task that
was cognitively engaging but not stressful. Saliva samples (assayed for sAA and cortisol), blood pressure, and heart
rate were taken before (baseline) and 15 minutes after the computerized task.
Results: Systolic and diastolic blood pressure and sAA activity increased across the laboratory session (F’s > 9.20,
p’s < 0.05); salivary cortisol levels decreased (F = 16.17, p < 0.05). There were no main effects for caffeine administration
on sAA, salivary cortisol, or cardiovascular measures, and caffeine did not interact with the task to alter these measures.
Conclusions: Laboratory administered caffeine does not alter sAA activity, even when sAA activity is stimulated by
participating in a cognitively engaging task. These data demonstrate that caffeine administration does not affect sAA
activity, at least in healthy young men who regularly consume caffeine. Results support recent findings that basal
caffeine levels in habitual caffeine users are not associated with basal sAA activity and that daily caffeine intake and
diurnal sAA activity are not related.
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This report is a follow up experiment to our recently
published data on the effects of stress and caffeine on
salivary alpha amylase (sAA) in healthy young men [1].
The health effects of caffeine and/or coffee consumption
continue to be debated (e.g., [2,3]). Caffeine is a central
nervous system stimulant that releases catecholamines
and glucocorticoids and elevates blood pressure (see [4]
for review; [5]). We recently reported that caffeine and* Correspondence: lcklein@psu.edu
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reproduction in any medium, provided the orstress together stimulate the release of salivary alpha
amylase (sAA) [1], a protein involved in oral mucosal
immunity [6] and carbohydrate digestion [7]. It has been
suggested that sAA also is a potential biomarker of sym-
pathetic nervous system (SNS) activity (see [8-10] for
reviews). For example, we recently reported that salivary
caffeine levels following caffeine and stress administration
were positively correlated with sAA activity in a controlled
laboratory setting [1]. These results extend correlational
field study finding that self-reported daily caffeine intake,
along with stress exposure, is associated with increased
sAA levels [11,12].
Caffeine and stress may stimulate sAA activity via SNS
activation (for review, see [13]). Caffeine bioavailability
may be altered in unanticipated ways as a result of stress
exposure on the pharmacokinetic profile of caffeine andd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Age and body mass indices (BMI) of men in each








Age (years) 22.00 ± 0.60 20.67 ± 0.58 21.07 ± 0.80
Body mass index (kg/m2) 23.43 ± 0.70 23.64 ± 0.80 23.11 ± 0.57
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tion (e.g., [14]). Therefore, it is possible that stress ex-
posure in the presence of caffeine administration may
interact in important physiological ways that alter sAA
activity. Stress in the absence of caffeine results in in-
creased sAA activity (for review see [9]), but the effects
of caffeine on sAA activity in the absence of stress are
not widely known.
Recent data suggest that caffeine alone may not alter
sAA activity [1]. We reported that basal caffeine levels in
habitual caffeine users do not appear to be associated with
basal sAA activity [1]. Further, daily caffeine intake does
not appear to affect diurnal sAA patterns [13]. However,
the direct effects of caffeine on sAA activity remain un-
known. Therefore, we conducted a controlled laboratory
experiment to examine the effects of caffeine administra-
tion on sAA activity in healthy young men who regularly
consumed caffeine (i.e., at least 50 mg of caffeine per day).
Participants were asked to complete a computerized task
that was engaging but not stressful to allow for the exam-
ination of caffeine’s influence on sAA without activating
a classic stress response as indicated by hypothalamic-
pituitary-adrenal axis activity (i.e., salivary cortisol ele-
vations [15]). We hypothesized that the task, but not
caffeine, would increase sAA activity.
Methods
Participants
Forty-five healthy men (18–30 years old; M = 21.24 ± 0.39
years), were recruited to participate in a study examining
caffeine and task performance through flyers posted in the
local community and on the Penn State campus. Sex dif-
ferences in caffeine pharmacokinetics can alter caffeine
metabolism and absorption in unanticipated ways [16],
therefore, we only included men in this initial study. Inter-
ested individuals were screened by a trained research
assistant in a telephone interview that reviewed health his-
tory. Eligibility criteria were identical to those in a previ-
ous study reported by our laboratory [1]. Specifically,
participants were daily caffeine users who consumed at
least 50 mg of caffeine per day (e.g., 8 oz cup of coffee, 12
oz can caffeinated soda). Respondents were excluded for
significant health problems and the use of medications or
drugs that could affect interpretation of neuroendocrine
or cardiovascular data, could alter caffeine metabolism, or
potentially could harm the participant if caffeine were ad-
ministered, including history of: smoking or nicotine use,
chronic medical conditions, medication use for any chronic
physical and/or mental health conditions, and medications
that could alter salivary biomarker data (e.g., oral or pa-
renteral corticosteroids within prior 3 months, over-the-
counter stimulants, flu/cold medications, caffeine- or
ephedrine-containing supplements, cimetidine, quinolones,
verapamil). Further, individuals with obesity (greater than140% of ideal body weight) were excluded as determined
by body mass index (BMI; weight/height2) > 30 [17] con-
firmed during the lab visit. The Center for Epidemiological
Studies Depression Scale (CES-D) [18] was administered
to screen (and exclude) for symptoms of depression.
Mean BMI did not differ across experimental groups
(see Table 1). Seventy-six percent of the participants were
Caucasian (N = 34), 11% were African American (N = 5),
9% were Asian (N = 4), and 4% were self-described as
“other” (N = 2). Ethnicity was equally represented across
the three experimental groups [χ2(6, 45) = 0.28, n.s.]. All
participants were high school graduates; 91% of partici-
pants had completed some college, and 9% had earned
higher than a college degree.Experimental protocol
Overview
The experimental protocol is identical to a previously pub-
lished experiment with the exception of the air traffic
controller task described below [1]. Eligible participants
refrained from taking daily vitamins on the day of their
session, ate a low-fat lunch by 1100 hrs, and avoided
caffeine consumption 4 hours prior to their lab session.
Participants arrived at the Penn State University General
Clinical Research Center (GCRC) on the day of their lab
session. All sessions started at 1300 hrs. Following in-
formed consent by a trained research assistant (CAW or
JMB), a certified nurse practitioner confirmed health sta-
tus and study eligibility. Participants then were asked to
complete a demographic survey and comprehensive meas-
ure of daily caffeine use. Next, a standard blood pres-
sure cuff (Dinamap Compact Blood Pressure Monitor,
Critikon, Tampa, FL) was placed on the non-dominant
arm to collect systolic blood pressure (SBP), diastolic
blood pressure (DBP), and heart rate (HR). Blood pressure
values from this automated oscillometric blood pressure
monitor are highly, positively correlated with intra-arterial
and ambulatory blood pressure measurements [19,20].
After cuff placement, a sample blood pressure reading was
taken to ensure that blood pressure levels fell within an
acceptable range (i.e., SBP <140 mmHg, DBP <90 mmHg,
HR <100 beats per minute). All participants met these
criteria.
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Participants were asked to sit quietly for 10 minutes while
5 baseline blood pressure readings were taken automatically
at 2-minute intervals. Participants next were asked to give a
saliva sample by rolling a cotton swab across their tongue
(without chewing on the swab) for 2 minutes and then pla-
cing it into a saliva collection tube (Salivette; Sarstedt, Inc.,
Newton, NC). Saliva samples immediately were placed on
ice until transferred to a minus 80 degree low-temperature
freezer for later assessment of sAA and cortisol. Parti-
cipants then were asked to complete three computerized
tasks that measured working memory, reaction time, and
visual attention (results not reported here), during which
time blood pressure and HR were recorded every 2 mi-
nutes. Together, these 3 computerized tasks took 3–5 mi-
nutes to complete.
Caffeine administration
Following the computer tasks, participants were asked
to swallow two gelatin capsules with a glass of water.
Details about the capsules are reported in Klein et al.
[1]. Each capsule contained either methylcellulose (pla-
cebo; Spectrum Chemicals, Gardena, CA) or a 200 mg
Vivarin® (GlaxoSmithKline, Philadelphia, PA) pill. Using
a randomized double-blind procedure, participants in
the placebo group (N = 15) received two methylcellulose
capsules, participants in the 200 mg caffeine group (N =
15) received 1 methylcellulose and 1 caffeine capsule, and
participants in the 400 mg caffeine group (N = 15) re-
ceived 2 caffeine capsules. This caffeine administration
paradigm was selected based on previously published
studies (e.g., [1,21,22]) and to parallel caffeine consump-
tion outside the lab where individuals consume caffeine
in the form of beverages (e.g., sodas, coffee) and food
(e.g., chocolate).
Based on our prior research [1], participants waited 20
minutes following capsule administration to allow for
adequate caffeine absorption. This rest period ensured
that participants completed the computerized task when
plasma caffeine levels were on the ascending limb of the
absorption curve [23,24]. Blood pressure and HR read-
ings were taken every 2 minutes. This caffeine adminis-
tration method and the timing of saliva collection results
in a dose-dependent increase in caffeine and caffeine
metabolite levels [1].
Air traffic controller task
The air traffic controller task (i.e., Argus; [25]) is an inter-
active, engaging task requiring cognitive, perceptual, and
motor processing. Moving targets appear on the computer
screen and the subject must classify as many targets as
possible in 2, 10-minute-sessions. The task took 20 mi-
nutes to complete; blood pressure and HR were recorded
every minute during this time period.Recovery
Participants next repeated the 3 computerized tasks that
they completed during baseline (i.e., working memory,
reaction time, signal detection), rest for a 15-minute re-
covery period to allow us to capture potential hormone
changes following the air traffic controller task [1,26], and
then provide a second saliva sample. Blood pressure and
HR were recorded every 2 minutes throughout this recov-
ery period. At the end of the session, participants were
paid $50 and a GCRC nurse informed them of their caf-
feine condition. All procedures were reviewed and ap-




On the day of assay, samples were allowed to thaw to
room temperature and then were centrifuged at 1500 × g
for 15 minutes to remove mucins and other particulate
matter that could interfere with the assay. Salivary cortisol
levels were assayed at the GCRC using commercially-
available enzyme immunoassay kits (DSL, Webster, TX).
The sample test volume was 25 ul. The assay had a lower
limit of sensitivity of 0.011 ug/dl, with an average inter-
and intra-assay covariance (%) of less than 8% and 5%, re-
spectively. The assay sensitivity (0.011 ug/dl) is based on
the minimum cortisol concentration required to produce
a three standard deviation from assay A0. Samples from
each participant were tested in duplicate in a single assay
batch. Values used in data analyses are the averages of
duplicate tests.
Salivary α-amylase (sAA)
Salivary α-amylase was measured at Salimetrics, LLC
(State College, PA) using a kinetic reaction assay [27].
The sample test volume was 10 ul. The assay had an
average inter- and intra-assay covariance (%) of less than
6% and 7.5%, respectively. Saliva samples from each par-
ticipant were tested in singlet in a single assay batch per
assay guidelines.
Blood pressure and heart rate
Systolic blood pressure, DBP, and HR readings were aver-
aged across each experimental time period to derive mean
baseline (5 readings), challenge (16 readings), and recovery
(6 readings) measures for each participant [1].
Statistical analyses
Square root transformations were applied to the sAA
data because they were not normally distributed [1,8];
this transformation resulted in a normal distribution of
the data. Similarly, log-transformation of the cortisol
data resulted in a normal distribution [1,28]. Thus, all sAA
and cortisol statistical analyses are based on transformed
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Separate repeated-measures analysis of variance (RM-
ANOVA), with Caffeine Treatment (3 levels) as the
independent measure and Time as the within-subject
variable, were conducted to examine group differences
in sAA and cortisol levels during the baseline and recovery
phases of the experiment. A multivariate RM-ANOVA
that included SBP, DBP, and HR as the dependent mea-
sures was used to examine group differences across
baseline, task performance, and recovery. When appro-
priate, statistical interactions were examined using sep-
arate one-way ANOVAs, Tukey’s honestly significant
difference (HSD), and Bonferroni post-hoc analyses.
All significance tests were two-tailed and evaluated at
α = 0.05.Results
Blood pressure and heart rate
Systolic and diastolic blood pressure increased across
the laboratory session such that SBP and DBP levels did
not return to baseline among all participants [F(2,84) >
9.20, p’s < 0.05] (see Table 2). In contrast, HR levels
dropped across the session [F(2,84) < 9.80, p < 0.05] for
all participants. There were no main effects for caffeine
administration on SBP, DBP, or HR levels nor did caf-
feine interact with time to alter these cardiovascular
measures.Table 2 Laboratory-administered caffeine dosage (mg/kg) an
and diastolic (DBP) blood pressure (mmHg) and heart rate (b
treatment group (estimated marginal means ± SEM)
Placebo (N = 15)
Caffeine dosage (mg/kg) 0.00 ± 0.00
Systolic blood pressure (mmHg)
Baseline 112.76 ± 2.06
Task performance 113.54 ± 2.44
Recovery 114.93 ± 2.202,3
Diastolic blood pressure (mmHg)
Baseline 65.16 ± 1.67
Task performance 65.55 ± 1.91
Recovery 70.73 ± 1.742,4
Heart rate (BPM)
Baseline 64.84 ± 2.29
Task performance 66.52 ± 2.24
Recovery 64.13 ± 2.002,5
1Caffeine treatment effect (200 mg < 400 mg), p < 0.0001.
2Time effect, p < 0.05.
3Baseline = Task Performance < Recovery, p < 0.05.
4Baseline < Task Performance < Recovery, p < 0.05.
5Baseline = Task Performance > Recovery, p < 0.05.Salivary cortisol
Baseline salivary cortisol levels did not differ among the
caffeine groups and cortisol levels decreased across the
laboratory session across all participants [F(1,42) = 5.77,
p < 0.05]. Caffeine administration did not alter salivary
cortisol levels and there was no time X caffeine group
interaction (Figure 1).
Salivary α-amylase (sAA)
Baseline sAA activity also did not differ among the
caffeine groups. Overall, the increased sAA activity
across all participants [F(1,42) = 16.17, p < 0.05]. How-
ever, similar to cortisol, caffeine did not alter sAA activ-
ity and there was no statistically significant caffeine X
time interaction.
Discussion
We examined the effects of caffeine administration on
salivary α-amylase (sAA) activity in response to an en-
gaging, non-stressful task in healthy young men who
consumed caffeine on a daily basis (i.e., at least 50 mg of
caffeine). Participants were asked to engage in a comput-
erized task that did not elicit a hypothalamic-pituitary-
adrenal axis stress response (i.e., salivary cortisol). We
found that laboratory administered caffeine does not
alter sAA activity, even when sAA activity is stimulated
by participating in a cognitive computer task. These data
support recent findings that basal caffeine levels in ha-
bitual caffeine users are not associated with basal sAAd baseline, task performance, and recovery systolic (SBP)
eats per minute; BPM) levels among men in each caffeine
Caffeine treatment groups
200 mg (N = 15) 400 mg (N = 15)
2.64 ± 0.091 5.51 ± 0.281
116.76 ± 2.06 116.45 ± 2.06
116.26 ± 2.44 121.02 ± 2.44
120.35 ± 2.202,3 122.20 ± 2.202,3
65.33 ± 1.67 65.43 ± 1.67
67.98 ± 1.91 68.99 ± 1.91
70.73 ± 1.742,4 70.93 ± 1.742,4
65.49 ± 2.29 67.25 ± 2.29
65.19 ± 2.24 68.74 ± 2.24
61.73 ± 2.002,5 63.56 ± 2.002,5
BA
Figure 1 Salivary cortisol (ng/mL) and salivary alpha-amylase
(U/mL) among men administered no caffeine, 200 mg or 400
mg of caffeine at baseline (before caffeine administration) and
recovery (15 min following cessation of air traffic controller)
(unadjusted means + SEM). (A) Mean salivary cortisol levels
(B) mean salivary alpha-amylase levels.
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sAA activity are not related [13]. Our results are the first
to demonstrate that caffeine administration does not
affect sAA activity, at least in healthy young men who
regularly consume caffeine.
The lack of a cortisol or cardiovascular response to caf-
feine administration is consistent with earlier reports that
caffeine’s endocrine and/or cardiovascular effects may be
most apparent in vulnerable populations such as individ-
uals at risk for hypertension in the presence of a stressor
(e.g., [29,30]). In addition, cardiovascular responses can at-
tenuate to repeated caffeine exposures such as daily con-
sumption, suggesting that nonsignificant blood pressureand heart rate responses to the caffeine manipulation may
be the result of habituation [31,32].
This study included a limited number of indices of the
sympathetic nervous system (sAA, blood pressure, heart
rate) across two time points. As activity and reactivity of
these measures is also influenced by the parasympathetic
branch of the autonomic nervous system (ANS) one might
consider adding purely sympathetic measures (such as
electrodermal activity) in future research. Such additional
laboratory-based experiments are needed to delineate the
mechanisms through which caffeine may or may not alter
ANS activity. These studies should have a more inclusive
ANS panel of biomarkers, such as plasma catecholamines
and heart rate variability, and include caffeine administra-
tion both with and without stress across individuals. Fur-
ther, men and women should be included in these studies,
along with varying caffeine dosages, and multiple ANS as-
sessments across the day.Conclusions
Laboratory administered caffeine does not alter sAA activ-
ity, even when sAA activity is stimulated by participating
in a cognitively engaging task. These data demonstrate
that caffeine administration does not affect sAA activity,
at least in healthy young men who regularly consume caf-
feine. Results support recent findings that basal caffeine
levels in habitual caffeine users are not associated with
basal sAA activity and that daily caffeine intake and diur-
nal sAA activity are not related.
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